Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma

Ilaria Buondonno, Elena Gazzano, Elisa Tavanti, Konstantin Chegaev, Joanna Kopecka, Marilù Fanelli, Barbara Rolando, Roberta Fruttero, Alberto Gasco, Claudia Hattinger, Massimo Serra, Chiara Riganti

Research output: Contribution to journalArticle

Abstract

Doxorubicin is one of the most effective drugs for the first-line treatment of high-grade osteosarcoma. Several studies have demonstrated that the major cause for doxorubicin resistance in osteosarcoma is the increased expression of the drug efflux transporter ABCB1/P-glycoprotein (Pgp). We recently identified a library of H2S-releasing doxorubicins (Sdox) that were more effective than doxorubicin against resistant osteosarcoma cells. Here we investigated the molecular mechanisms of the higher efficacy of Sdox in human osteosarcoma cells with increasing resistance to doxorubicin. Differently from doxorubicin, Sdox preferentially accumulated within the endoplasmic reticulum (ER), and its accumulation was only modestly reduced in Pgp-expressing osteosarcoma cells. The increase in doxorubicin resistance was paralleled by the progressive down-regulation of genes of ER-associated protein degradation/ER-quality control (ERAD/ERQC), two processes that remove misfolded proteins and protect cell from ER stress-triggered apoptosis. Sdox, that sulfhydrated ER-associated proteins and promoted their subsequent ubiquitination, up-regulated ERAD/ERQC genes. This up-regulation, however, was insufficient to protect cells, since Sdox activated ER stress-dependent apoptotic pathways, e.g., the C/EBP-β LIP/CHOP/PUMA/caspases 12-7-3 axis. Sdox also promoted the sulfhydration of Pgp that was subsequently ubiquitinated: this process further enhanced Sdox retention and toxicity in resistant cells. Our work suggests that Sdox overcomes doxorubicin resistance in osteosarcoma cells by at least two mechanisms: it induces the degradation of Pgp following its sulfhydration and produces a huge misfolding of ER-associated proteins, triggering ER-dependent apoptosis. Sdox may represent the prototype of innovative anthracyclines, effective against doxorubicin-resistant/Pgp-expressing osteosarcoma cells by perturbing the ER functions.

Original languageEnglish
Pages (from-to)609-625
Number of pages17
JournalCellular and Molecular Life Sciences
Volume76
Issue number3
DOIs
Publication statusE-pub ahead of print - Nov 14 2018

Fingerprint

Osteosarcoma
Endoplasmic Reticulum
Doxorubicin
P-Glycoprotein
Endoplasmic Reticulum Stress
Quality Control
Proteolysis
Caspase 12
Endoplasmic Reticulum-Associated Degradation
Apoptosis
Caspase 7
Proteins
Ubiquitination
Anthracyclines
Pharmaceutical Preparations
Genes
Libraries
Up-Regulation
Down-Regulation

Keywords

  • Endoplasmic reticulum stress
  • Endoplasmic reticulum-associated protein degradation
  • H2S-releasing doxorubicin
  • Osteosarcoma
  • P-glycoprotein

Cite this

Buondonno, I., Gazzano, E., Tavanti, E., Chegaev, K., Kopecka, J., Fanelli, M., ... Riganti, C. (2018). Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma. Cellular and Molecular Life Sciences, 76(3), 609-625. https://doi.org/10.1007/s00018-018-2967-9

Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma. / Buondonno, Ilaria; Gazzano, Elena; Tavanti, Elisa; Chegaev, Konstantin; Kopecka, Joanna; Fanelli, Marilù; Rolando, Barbara; Fruttero, Roberta; Gasco, Alberto; Hattinger, Claudia; Serra, Massimo; Riganti, Chiara.

In: Cellular and Molecular Life Sciences, Vol. 76, No. 3, 14.11.2018, p. 609-625.

Research output: Contribution to journalArticle

Buondonno, I, Gazzano, E, Tavanti, E, Chegaev, K, Kopecka, J, Fanelli, M, Rolando, B, Fruttero, R, Gasco, A, Hattinger, C, Serra, M & Riganti, C 2018, 'Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma', Cellular and Molecular Life Sciences, vol. 76, no. 3, pp. 609-625. https://doi.org/10.1007/s00018-018-2967-9
Buondonno, Ilaria ; Gazzano, Elena ; Tavanti, Elisa ; Chegaev, Konstantin ; Kopecka, Joanna ; Fanelli, Marilù ; Rolando, Barbara ; Fruttero, Roberta ; Gasco, Alberto ; Hattinger, Claudia ; Serra, Massimo ; Riganti, Chiara. / Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma. In: Cellular and Molecular Life Sciences. 2018 ; Vol. 76, No. 3. pp. 609-625.
@article{04ff3c3c552e4ecd86e1d66b8ad56014,
title = "Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma",
abstract = "Doxorubicin is one of the most effective drugs for the first-line treatment of high-grade osteosarcoma. Several studies have demonstrated that the major cause for doxorubicin resistance in osteosarcoma is the increased expression of the drug efflux transporter ABCB1/P-glycoprotein (Pgp). We recently identified a library of H2S-releasing doxorubicins (Sdox) that were more effective than doxorubicin against resistant osteosarcoma cells. Here we investigated the molecular mechanisms of the higher efficacy of Sdox in human osteosarcoma cells with increasing resistance to doxorubicin. Differently from doxorubicin, Sdox preferentially accumulated within the endoplasmic reticulum (ER), and its accumulation was only modestly reduced in Pgp-expressing osteosarcoma cells. The increase in doxorubicin resistance was paralleled by the progressive down-regulation of genes of ER-associated protein degradation/ER-quality control (ERAD/ERQC), two processes that remove misfolded proteins and protect cell from ER stress-triggered apoptosis. Sdox, that sulfhydrated ER-associated proteins and promoted their subsequent ubiquitination, up-regulated ERAD/ERQC genes. This up-regulation, however, was insufficient to protect cells, since Sdox activated ER stress-dependent apoptotic pathways, e.g., the C/EBP-β LIP/CHOP/PUMA/caspases 12-7-3 axis. Sdox also promoted the sulfhydration of Pgp that was subsequently ubiquitinated: this process further enhanced Sdox retention and toxicity in resistant cells. Our work suggests that Sdox overcomes doxorubicin resistance in osteosarcoma cells by at least two mechanisms: it induces the degradation of Pgp following its sulfhydration and produces a huge misfolding of ER-associated proteins, triggering ER-dependent apoptosis. Sdox may represent the prototype of innovative anthracyclines, effective against doxorubicin-resistant/Pgp-expressing osteosarcoma cells by perturbing the ER functions.",
keywords = "Endoplasmic reticulum stress, Endoplasmic reticulum-associated protein degradation, H2S-releasing doxorubicin, Osteosarcoma, P-glycoprotein",
author = "Ilaria Buondonno and Elena Gazzano and Elisa Tavanti and Konstantin Chegaev and Joanna Kopecka and Maril{\`u} Fanelli and Barbara Rolando and Roberta Fruttero and Alberto Gasco and Claudia Hattinger and Massimo Serra and Chiara Riganti",
year = "2018",
month = "11",
day = "14",
doi = "10.1007/s00018-018-2967-9",
language = "English",
volume = "76",
pages = "609--625",
journal = "Cellular and Molecular Life Sciences",
issn = "1420-682X",
publisher = "Birkhauser Verlag Basel",
number = "3",

}

TY - JOUR

T1 - Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma

AU - Buondonno, Ilaria

AU - Gazzano, Elena

AU - Tavanti, Elisa

AU - Chegaev, Konstantin

AU - Kopecka, Joanna

AU - Fanelli, Marilù

AU - Rolando, Barbara

AU - Fruttero, Roberta

AU - Gasco, Alberto

AU - Hattinger, Claudia

AU - Serra, Massimo

AU - Riganti, Chiara

PY - 2018/11/14

Y1 - 2018/11/14

N2 - Doxorubicin is one of the most effective drugs for the first-line treatment of high-grade osteosarcoma. Several studies have demonstrated that the major cause for doxorubicin resistance in osteosarcoma is the increased expression of the drug efflux transporter ABCB1/P-glycoprotein (Pgp). We recently identified a library of H2S-releasing doxorubicins (Sdox) that were more effective than doxorubicin against resistant osteosarcoma cells. Here we investigated the molecular mechanisms of the higher efficacy of Sdox in human osteosarcoma cells with increasing resistance to doxorubicin. Differently from doxorubicin, Sdox preferentially accumulated within the endoplasmic reticulum (ER), and its accumulation was only modestly reduced in Pgp-expressing osteosarcoma cells. The increase in doxorubicin resistance was paralleled by the progressive down-regulation of genes of ER-associated protein degradation/ER-quality control (ERAD/ERQC), two processes that remove misfolded proteins and protect cell from ER stress-triggered apoptosis. Sdox, that sulfhydrated ER-associated proteins and promoted their subsequent ubiquitination, up-regulated ERAD/ERQC genes. This up-regulation, however, was insufficient to protect cells, since Sdox activated ER stress-dependent apoptotic pathways, e.g., the C/EBP-β LIP/CHOP/PUMA/caspases 12-7-3 axis. Sdox also promoted the sulfhydration of Pgp that was subsequently ubiquitinated: this process further enhanced Sdox retention and toxicity in resistant cells. Our work suggests that Sdox overcomes doxorubicin resistance in osteosarcoma cells by at least two mechanisms: it induces the degradation of Pgp following its sulfhydration and produces a huge misfolding of ER-associated proteins, triggering ER-dependent apoptosis. Sdox may represent the prototype of innovative anthracyclines, effective against doxorubicin-resistant/Pgp-expressing osteosarcoma cells by perturbing the ER functions.

AB - Doxorubicin is one of the most effective drugs for the first-line treatment of high-grade osteosarcoma. Several studies have demonstrated that the major cause for doxorubicin resistance in osteosarcoma is the increased expression of the drug efflux transporter ABCB1/P-glycoprotein (Pgp). We recently identified a library of H2S-releasing doxorubicins (Sdox) that were more effective than doxorubicin against resistant osteosarcoma cells. Here we investigated the molecular mechanisms of the higher efficacy of Sdox in human osteosarcoma cells with increasing resistance to doxorubicin. Differently from doxorubicin, Sdox preferentially accumulated within the endoplasmic reticulum (ER), and its accumulation was only modestly reduced in Pgp-expressing osteosarcoma cells. The increase in doxorubicin resistance was paralleled by the progressive down-regulation of genes of ER-associated protein degradation/ER-quality control (ERAD/ERQC), two processes that remove misfolded proteins and protect cell from ER stress-triggered apoptosis. Sdox, that sulfhydrated ER-associated proteins and promoted their subsequent ubiquitination, up-regulated ERAD/ERQC genes. This up-regulation, however, was insufficient to protect cells, since Sdox activated ER stress-dependent apoptotic pathways, e.g., the C/EBP-β LIP/CHOP/PUMA/caspases 12-7-3 axis. Sdox also promoted the sulfhydration of Pgp that was subsequently ubiquitinated: this process further enhanced Sdox retention and toxicity in resistant cells. Our work suggests that Sdox overcomes doxorubicin resistance in osteosarcoma cells by at least two mechanisms: it induces the degradation of Pgp following its sulfhydration and produces a huge misfolding of ER-associated proteins, triggering ER-dependent apoptosis. Sdox may represent the prototype of innovative anthracyclines, effective against doxorubicin-resistant/Pgp-expressing osteosarcoma cells by perturbing the ER functions.

KW - Endoplasmic reticulum stress

KW - Endoplasmic reticulum-associated protein degradation

KW - H2S-releasing doxorubicin

KW - Osteosarcoma

KW - P-glycoprotein

U2 - 10.1007/s00018-018-2967-9

DO - 10.1007/s00018-018-2967-9

M3 - Article

C2 - 30430199

VL - 76

SP - 609

EP - 625

JO - Cellular and Molecular Life Sciences

JF - Cellular and Molecular Life Sciences

SN - 1420-682X

IS - 3

ER -